Acquisition focused on lead clinical-stage program ICT01 in acute myeloid leukemia, where data from the ongoing Phase I/II EVICTION trial showed high treatment response ICT01 has the potential to be a ...

IPN10200 is a recombinant, first-in-class molecule uniquely engineered to generate increased receptor affinity and internalization that produces a longer duration of action, optimized for safety and ...

Ipsen (ENXTPA:IPN) is back on investors’ radar, and not because of any one specific headline. Sometimes, a stock’s recent price swings themselves are the story, especially when they diverge from a ...

Ipsen recently celebrated a significant milestone with Health Canada's approval of Bylvay™ (odevixibat) for treating cholestatic pruritus in Alagille Syndrome patients. This product-related ...

Ipsen ((GB:0MH6)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to ...

Imagine going to work every day knowing that what you do directly contributes to improving the lives of people with rare and life-limiting conditions. That’s what life is like for Bénédicte ...

PARIS, FRANCE, 06 May 2025 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty care-driven biopharmaceutical company, announced today the appointment of Laura Réveillon, PhD as EVP, Strategy & ...

CEO David Loew emphasized Ipsen’s sustained growth in 2024, with total sales increasing by 9.9%. He highlighted the strong performance of the ex-Somatuline portfolio, which grew by 12.2%, and outlined ...

French drugmaker Ipsen (OTCPK:IPSEY) (OTCPK:IPSEF) announced Friday that an expert panel of the European Medicines Agency recommended marketing authorizations for two of its liver-targeting drugs.

Ipsen is spreading its bets in a fast-growing and competitive area of cancer drug research, striking a deal for a novel Foreseen Biotechnology antibody drug conjugate (ADC) that’s on track for its ...

Ipsen and Foreseen Biotechnology announced an exclusive licensing agreement for FS001, an antibody drug conjugate (ADC), on Thursday morning. The deal, which could reach up to $1.03 billion, grants ...